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Background: Glucocorticoid receptor (GR) activity plays a role in many aspects of human 
physiology and may play a crucial role in chemotherapy resistance in a wide variety of solid 
tumors. A novel immunohistochemistry (IHC) based assay has been previously developed and 
validated in order to assess GR immunoreactivity in triple-negative breast cancer. The current 
study investigates the standardized use of this validated assay to assess GR expression in a broad 
range of solid tumor malignancies.
Methods: Archived formalin-fixed paraffin-embedded tumor bank samples (n=236) from 20 
different solid tumor types were analyzed immunohistochemically. Nuclear staining was reported 
based on the H-score method using differential intensity scores (0, 1+, 2+, or 3+) with the percent 
stained (out of at least 100 carcinoma cells) recorded at each intensity.
Results: GR was expressed in all tumor types that had been evaluated. Renal cell carcinoma, 
sarcoma, cervical cancer, and melanoma were those with the highest mean H-scores, indicating 
high levels of GR expression. Colon, endometrial, and gastric cancers had lower GR staining 
percentages and intensities, resulting in the lowest mean H-scores.
Conclusion: A validated IHC assay revealed GR immunoreactivity in all solid tumor types 
studied and allowed for standardized comparison of reactivity among the different malignancies.
Impact: Baseline expression levels of GR may be a useful biomarker when pharmaceutically 
targeting GR in research or clinical setting.
Keywords: glucocorticoid receptor expression, immunohistochemistry, solid tumors
Introduction
Glucocorticoid receptor (GR), a member of the steroid nuclear receptor superfamily, 
is responsible for modulating many processes, including cell homeostasis, cellular 
development, metabolic function,1–4 immune function,5 and central nervous system 
and psychiatric function.6,7 In oncology, GR has been implicated in the development 
of cancer cell resistance by modulating the intracellular apoptosis balance point and 
influencing several well-documented cascade mechanisms.8 GR modulation of gene 
expression is complex and involves the binding of ligand and receptor in the cyto-
plasm, dissociation of heat shock proteins, and homodimerization and translocation 
of the ligand/receptor complex to the nucleus.3 The ligand/receptor complex then 
binds directly to the DNA and acts as a transcription factor for multiple gene prod-
ucts. This activity is further influenced by the complex environment of coactivator 
and corepressor molecules, which contribute additional effects to gene expression.2,6 
Investigators have identified the role of GR in the development of chemotherapy 
resistance in experimental models involving tumors of epithelial origin, especially 
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triple-negative breast cancer (TNBC), prostate cancer, and 
ovarian cancer.9–15
The addition of the GR agonist, dexamethasone, to 
cell line chemotherapy models reduces apoptosis and 
increases transcription of pro-cell-survival genes. These 
effects were reversed in the presence of the GR antagonist, 
mifepristone.15–17 A TNBC cell line MDA-MB-231 xeno-
graft model demonstrated that addition of dexamethasone 
reduced cell death induced by paclitaxel, whereas the 
addition of mifepristone enhanced the efficacy of the 
taxanes.16 The effect of mifepristone has been replicated 
in in vitro and in vivo experiments across multiple cancer 
cell lines and in combination with multiple chemothera-
peutic agents.14–17
These in vitro data indicate that glucocorticoids, whether 
endogenous or exogenous, may cause expression of pro-
survival/antiapoptotic genes and protect tumor cells from 
the effects of chemotherapy.18,19 Conversely, benefits of 
GR antagonists have been shown preclinically in several 
tumor types expressing GR including TNBC, ovarian, lung, 
and prostate cancer.9–14,16,17,20 In addition to the preclinical 
evidence,16 clinical evidence21–23 suggests that GR expres-
sion plays a substantial role in TNBC. These findings have 
considerable clinical implications as the coadministration of 
glucocorticoids is common to counteract hypersensitivity to 
various treatments as well as nausea. 
An immunohistochemistry (IHC) assay has been devel-
oped and validated for evaluating GR expression in TNBC.24 
Several clinical trials are currently evaluating GR antagonists 
in conjunction with chemotherapy in patients with TNBC.25 
These studies further measure GR tumor expression using 
the validated IHC assay. During development of the previ-
ously reported TNBC assay, 50 archival, formalin-fixed 
paraffin-embedded (FFPE) tissue samples of TNBC from 
individual treatment-naïve patients, collected as diagnostic 
tissue blocks and stored in a commercial tissue bank, were 
evaluated. While the earlier literature suggested rates of GR 
positivity of ~25%–50% in TNBC samples,26–28 rates based 
on the IHC assay were ≥80%24 using a minimum cutoff of 
10% tumor cells staining positively.
The objective of this exploratory GR expression study was 
to extend this research beyond TNBC by using the previously 
developed IHC GR assay to survey the degree of GR expres-
sion across other tumor types. Little is known about rates of 
GR expression in other tumor types even though the role of 
GR in chemotherapy resistance has been suggested in many 
tumors of epithelial origin.9–13 As understanding of the role 
of GR in oncology progresses, the findings from this study 
may guide decisions about how to successfully introduce GR 
antagonists into clinical testing. 
Methods and materials
GR IHC protocol
For each of the 20 selected tumor types, archival FFPE tumor 
bank tissues were randomly chosen for this study. With 
the exception of the pancreatic cancer samples that were 
purchased from Pantomics Inc. (Richmond, CA, USA), all 
other tissues samples were obtained from the QualTek tissue 
bank (QualTek Molecular Laboratories, Newtown, PA, USA). 
These tumor tissues were ethically acquired from various 
clinical sites with diverse patient populations with personal 
identifiers redacted. 
The FFPE tumor tissues were sectioned (4–5 μm) onto 
slides with a positive charge (Fisher ProbeOn Plus™; Thermo 
Fisher Scientific, Waltham, MA, USA) and dry heated for 1 h 
at 65°C within 1 week of testing. Deparaffinization included 
a series of four 100% xylene changes followed by rehydra-
tion with a graded series of ethanol (100%, 70%, 30%) to 
distilled water.
Based on a previous publication, rabbit monoclonal anti-
body anti-GR (D8H2; Cell Signaling Technology [#3660S], 
Danvers, MA, USA), was chosen from three different GR 
antibody candidates for further assay development and 
validation.24
Antigen retrieval consisted of a 20-min incubation of 
slides in Citra Plus Target Retrieval Solution (BioGenex 
[catalog number HK080-9K], Fremont, CA, USA), heated to 
98°C with a commercial steamer (Black and Decker HS1000 
model steamer; Black and Decker, Baltimore, MD, USA). 
Following a 5-min cool down, slides were transferred onto 
an automated IHC platform (TechMate™ 500 or 1000 with 
WorkMate software version 3.96; Roche Diagnostics, Oro 
Valley, AZ, USA). All reagent changes were automated, 
including all detection kit steps (Rabbit Polink2+ HRP and 
DAB chromogen; Golden Bridge International, [catalog 
numbers D39-110 and C09-100], Bothell, WA, USA), a 
protein blocking step (QualTek proprietary reagent), primary 
antibody incubation (anti-GR [D8H2]; Cell Signaling Tech-
nology [catalog number 3660S]; diluted to 1:1,750 in pri-
mary antibody diluent [QualTek proprietary]), a peroxidase 
blocking step (3% United States Pharmacopeia H
2
O
2
, with 
~0.02% v/v Tween® 20 detergent; Thermo Fisher Scientific), 
hematoxylin counterstaining and all intervening washes 
(tris-buffered saline containing 0.02% v/v Tween 20), by a 
capillary gap process29 at room temperature (25°C) using the 
previously optimized assay conditions.24 The slides were then 
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dehydrated in a series of ethanol (95%, 100%) and 100% 
xylene changes, and mounted with a coverslip (CytosealTM 
XYL mounting media, Thermo Fisher Scientific).
Evaluation of GR expression in  
various tumors
The assay was previously validated24 in a Clinical Labora-
tory Investigation Amendment (CLIA)-accredited facility 
( QualTek Clinical Laboratories). GR expression levels, 
detected by the validated IHC assay, were evaluated in a panel 
of 20 tumor types (Table 1) using archival, treatment-naïve, 
FFPE tissue samples (individual or within tissue microarrays 
[TMAs]). Tissues included bladder cancer (n=10), breast 
cancer (non-TNBC) (n=10), cervical cancer (n=15), colon 
cancer (n=16), endometrial cancer (n=13), esophageal cancer 
(n=8), gall bladder cancer (n=10), gastric cancer (n=11), glio-
blastoma (n=8), head and neck cancer (n=10), hepatocellular 
carcinoma (n=10), lung cancer (n=17), melanoma (n=11), 
mesothelioma (n=8, including TMA [n=4; four cores each, 
1.5 mm; US Biomax, Inc., catalog number T392a, Rockville, 
MD, USA]), neuroendocrine cancer (n=11), ovarian cancer 
(n=11), pancreatic cancer (n=16, including TMA [two cores 
each, 2 mm]; Pantomics Inc. [catalog number PAC481]), 
prostate cancer (n=11), renal cell carcinoma (RCC) (n=10), 
and sarcoma (n=14). 
GR staining is sensitive to poor tissue fixation, common 
among nuclear antigens, and may result in a potential false-
negative IHC result. However, because GR strongly stains 
stromal cells (which act as an internal positive control), areas 
of poor fixation that would contribute to a false-negative 
result are easily identifiable. In such cases, those regions 
were not scored or the samples were rejected.
Tissue sections were scored for nuclear staining within 
tumor cells across the total evaluable area of the tissue. 
Staining within the cytoplasm of tumor cells or stroma was 
not scored. Necrotic regions, in situ carcinoma, and poorly 
fixed regions of the tissue were also excluded from scoring. 
GR reactivity was scored using differential intensity scores 
(0, null; 1+, low or weak; 2+, moderate; 3+, high or strong). 
A total percentage score (% of tumor cells staining ≥1+ 
intensity; ie, the sum of the percentage of cells at 1+, 2+, and 
3+ intensities) was used to semiquantitatively evaluate tumor 
expression of GR. Only samples with at least 100 invasive 
carcinoma cells were included. The H-score, which numerates 
staining ratios with respect to both intensity and frequency, 
was used to capture the pattern of nuclear staining observed. 
The H-score was calculated using the following formula: 
H-score = [(% at 0)×0]+[(% at 1+)×1]+[(% at 2+)×2]+ 
[(% at 3+)×3]. The H-score produces a continuous variable 
that ranges from 0 to 300. 
Results
GR staining was evaluated in 20 different tumor types 
(Table 1) with 236 total samples analyzed and 5–16 samples 
per tumor type (Table 2). Although GR staining is generally 
broad and is observed in most normal tissue, stromal stain-
ing served as an internal positive control to help identify 
samples to reject or regions to avoid during the scoring 
process. Positive and negative controls were included in all 
tests and were evaluated for appropriate reactivity before GR 
staining was evaluated.
GR reactivity was observed in the nuclei of all tumor cell 
types examined and was highly expressed in the majority 
of tumors (Table 2) with little to no cytoplasmic staining. 
Representative micrographs showing a range of staining 
intensities are provided in Figure 1. 
With GR staining depicted as a fraction of cells with 0, 
1+, 2+, and 3+ staining, melanoma, RCC, and sarcoma tumor 
samples show a high fraction of 2+ and 3+ staining, and few 
samples (<10%) show 0 staining. In contrast, >80% of colon, 
gastric, and endometrial cancer samples had no GR staining. 
For the other tumors evaluated, at least 50% of the tumors 
expressed 1+ to 3+ staining.
Evaluating GR expression of the tumor types by H-score 
(accounting for both intensity and frequency) versus fre-
quency of GR positivity showed similar results (Figures 2 
and 3). Several cancer types have high mean and median 
H-scores along with high variability of H-scores within 
tumor types. An exception is seen with melanoma, cervical 
cancer, RCC, and sarcoma tumor types. Their H-scores were 
high with little variability and the GR staining was uniformly 
high. Colon, gastric, and endometrial cancer were distinctly 
different from the other tumors by virtue of their very low 
GR staining intensity fraction and H-score. 
Table 1 Solid tumor types evaluated using glucocorticoid 
receptor IHC sensitivity screening
Bladder cancer 
Breast cancer (non-TNBC) 
Cervical cancer 
Colon cancer 
Endometrial cancer 
Esophageal cancer 
Gall bladder cancer 
Gastric cancer 
Glioblastoma 
Head and neck cancer 
Hepatocellular carcinoma 
Lung cancer 
Melanoma 
Mesothelioma 
Neuroendocrine cancer 
Ovarian cancer 
Pancreatic cancer 
Prostate cancer 
Renal cell carcinoma 
Sarcoma 
Abbreviations: IHC, immunohistochemical; TNBC, triple-negative breast cancer.
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The limited histologic subtypes that were analyzed (data 
not shown) indicated that GR expression varies by tumor 
subtype. This analysis showed that small-cell lung cancer 
(SCLC) has very low GR expression (mean H-score 81, 
range 0–230), whereas non-small-cell lung cancer (NSCLC) 
adenocarcinoma and squamous cell carcinoma have high GR 
expression (mean H-score 193, range 140–290, and 173, 
range 120–260, respectively). In the samples studied, the 
subtypes of the RCC were limited to clear cell type, all of 
high GR staining. The sarcoma tumor group included soft 
tissue sarcomas only, also all of high GR staining. 
Discussion 
GRs play an important role in tumor response to micro-
environment, and GRs have been implicated in tumor cell 
survival and response to chemotherapy.12–15,17,18,20 To date, GR 
expression has been reported only within a limited number 
of solid tumor types (eg, breast and colon),26–28,30 and assay 
results have been highly variable. Hence, the clinical rel-
evance of the results in the literature is difficult to interpret. 
A CLIA-validated,24 IHC-based, GR assay has been devel-
oped and assessments of 20 different tumor types have been 
standardized with more than 200 samples. Using surround-
ing tissues (ie, positively staining fibroblasts, endothelial 
cells, and a subset of lymphocytes) as an internal stromal 
control provides high confidence of antibody specificity to 
GR  protein. The antibody used in this assay, D8H2, is both 
specific and sensitive to the Leu368 region of both alpha and 
beta isoforms of the GR protein24 without cross-reactivity 
to the mineralocorticoid receptor and nonspecific binding. 
GR reactivity was observed in all 20 tumor types that 
had been evaluated, many of which had no prior published 
GR expression rates. GR staining was detectable at a wide 
range of intensities across and within the various tumor types. 
Applying the validated GR IHC assay, it was observed that 
GR expression varies by tumor type. Among the tumors with 
an overall high degree of GR staining, some tumors were con-
sistently high staining (clear cell RCC, soft tissue sarcoma, 
melanoma, and cervical cancer), and others showed great 
variability among individual samples. Colon, gastric, and 
endometrial cancer have very low GR staining by intensity 
and H-score, with the majority of samples showing no GR 
expression. As seen with the lung cancer samples evaluated, 
GR expression was different for SCLC and NSCLC. Further 
analyses of GR expression by other tumor subtypes is needed. 
As with most established tumor receptors that have 
been successfully targeted, much effort has been placed on 
correlating clinical outcomes with target expression levels 
and activity. The definition of what is considered “positive” 
for estrogen receptor (ER), progesterone receptor (PR), and 
human epidermal growth factor receptor 2 research31,32 has 
been modified over time. The definition of “positive” for 
Table 2 Immunohistochemistry scoring for glucocorticoid receptor status in 20 tumor types
Cancer type N Intensity staining ≥1+ (%) H-scorea
Mean (SD) Range Mean (SD) Range
Melanoma 11 94.1 (5.8) 80–100 241.8 (33.3) 180–290
Renal cell carcinoma 10 93.5 (7.1) 80–100 227.5 (48.9) 130–300
Sarcoma 14 92.9 (4.3) 85–100 212.9 (35.8) 155–270
Cervical 15 82.0 (21.5) 40–100 210.0 (75.6) 70–290
Head and neck 10 86.5 (7.5) 70–95 191.5 (37.7) 130–250
Hepatocellular carcinoma 10 82.0 (12.1) 60–95 185.0 (55.5) 90–265
Neuroendocrine 11 79.1 (33.2) 10–100 175.5 (88.3) 10–260
Mesothelioma 8 84.4 (13.7) 65–100 165.9 (50.1) 120–260
Glioblastoma 8 71.9 (28.0) 20–100 164.4 (80.3) 25–260
Lung 17 75.3 (30.8) 0–100 152.9 (84.8) 0–290
Esophageal 8 62.6 (42.8) 0–100 151.4 (113.0) 0–280
Prostate 11 85.9 (26.4) 10–100 144.5 (63.2) 10–220
Pancreas 16 78.3 (25.1) 30–100 131.1 (78.4) 30–280
Bladder 10 56.8 (46.0) 0–98 117.3 (99.9) 0–255
Breast (non-TNBC) 10 62.9 (44.1) 1–100 111.5 (89.3) 1–250
Gall bladder 10 73.5 (14.9) 50–95 108.5 (43.3) 70–205
Ovarian 11 57.7 (33.9) 0–100 106.8 (87.8) 0–240
Endometrial 13 17.5 (27.6) 0–95 32.5 (60.5) 0–215
Gastric 11 14.5 (26.9) 0–90 22.7 (53.1) 0–180
Colon 16 6.3 (22.4) 0–90 12.9 (47.3) 0–190
Note: aSorted by mean H-score.
Abbreviation: SD, standard deviation; TNBC, triple-negative breast cancer.
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both ER and PR decreased over time from ≥10% of tumor 
cells staining positive to ≥1%.31 Similar efforts are currently 
ongoing with programmed cell death protein 1 (PD1) and 
PD1-ligand 1 (PD-L1) therapies. Thus, the data were pre-
sented as intensity and frequency of staining across the 20 
tumor types, without applying a threshold cutoff. 
The wide range of staining intensity and H-scores seen 
warrants further research to understand the role of GR 
expression, both as a prognostic factor and as a predictive 
factor in the response to chemotherapy. For some tumor types 
(melanoma, sarcoma, and RCC), GR assessment may not be 
necessary due to the consistently high staining intensity and 
H-scores. Research is needed to determine if tumors with 
low staining and H-scores (colon, gastric, and endometrial 
cancers) are good candidates for GR-targeted therapeutics.
With the introduction of more selective GR antagonists, 
GR may become a relevant therapeutic target. Hence, this 
validated assay may provide new opportunities in developing 
companion diagnostic and predictive assays for GR expres-
sion. Establishing the optimal threshold for GR expression 
qualitatively or quantitatively that correlates with clinical 
benefit in patients with specific tumor types will require 
Figure 1 Representative micrographs of immunohistochemical GR staining in various tumor types showing variations in levels of staining.
Note: Tumors with ≥10% GR staining at the following intensities: 0, 1+, 2+, and 3+. 
Abbreviation: GR, glucocorticoid receptor; TNBC, triple-negative breast cancer.
High rates of GR staining
Melanoma 
0 [5%] 1+ [5%] 2+ [20%] 3+ [70%]
Sarcoma 
0 [10%] 1 [10%] 2 [30%] 3 [50%]
Cervical cancer
0 [10%] 1 [10%] 2 [30%] 3 [50%]
Moderate rates of GR staining
Prostate cancer
0 [5%] 1 [45%]  2 [30%] 3 [20%]
Breast cancer (non-TNBC)
0 [5%]  1 [90%]  2 [5%] 3 [0%]
Ovarian cancer
0 [40%] 1 [50%] 2 [10%]  3 [0%]
Low rates of GR staining
Gastric cancer
0 [90%]   1 [10%] 2 [0%] 3 [0%]
Colon cancer
0 [100%] 1 [0%] 2 [0%] 3 [0%]
Endometrial cancer
0 [95%] 1 [5%] 2 [0%] 3 [0%]
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larger studies with clinical endpoints. An initial assessment 
of GR as a therapeutic target and predictive factor is ongo-
ing in a clinical trial testing the selective GR modulator 
CORT125134 in combination with nab-paclitaxel in solid 
tumors (NCT02762981). 
The current assessment of GR positivity include the 
limited sample size and absence of subtyping within a tumor 
type. Furthermore, assessment of single sections of an FFPE 
sample may not completely represent GR distribution within 
the tumor and may only reflect a portion of a tumor. Also, GR 
expression may evolve in response to anticancer therapy and 
be further influenced by the use of concomitant medication, 
particularly those including steroids. This validated assay 
provides the first steps of assessing GR as a clinical surrogate 
and pharmacological target. Further studies will be needed 
to determine the most robust technical method to prepare 
samples through the course of treatment and to determine 
which quantitative assessment provides the strongest corre-
lation with receptor expression (eg, GR protein correlation 
with mRNA levels) and clinical outcomes. 
Conclusion
GR expression using a validated IHC assay showed that GR 
is expressed in multiple different solid tumor malignancies, 
and may be a predictive tool to guide the clinical develop-
ment of GR antagonists. Further clinical correlation will be 
needed to determine, within individual tumor types, what 
the optimal thresholds for GR expression will be for patient 
selection and stratification. 
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